Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

SEPTIN14 (Septin 14)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

EGFR-SEPTIN14 fusion	Non Small Cell Lung Cancer	EGFR-SEPTIN14 fusion	Non Small Cell Lung Cancer	icotinib Sensitive: C4 – Case Studies icotinib Sensitive : C4	icotinib Sensitive: C4 – Case Studies icotinib Sensitive : C4
EGFR-SEPTIN14 rearrangement	Lung Adenocarcinoma	EGFR-SEPTIN14 rearrangement	Lung Adenocarcinoma	icotinib Sensitive: C4 – Case Studies icotinib Sensitive : C4	icotinib Sensitive: C4 – Case Studies icotinib Sensitive : C4
APC V2194fs + EGFR amplification + EGFR-SEPTIN14 fusion	Gastric Cancer	APC V2194fs + EGFR amplification + EGFR-SEPTIN14 fusion	Gastric Cancer	nivolumab Resistant: C4 – Case Studies nivolumab Resistant : C4	nivolumab Resistant: C4 – Case Studies nivolumab Resistant : C4
EGFRvIII mutation + EGFR-SEPTIN14 fusion + EGFR amplification	Colorectal Cancer	EGFRvIII mutation + EGFR-SEPTIN14 fusion + EGFR amplification	Colorectal Cancer	erlotinib Resistant: C4 – Case Studies erlotinib Resistant : C4	erlotinib Resistant: C4 – Case Studies erlotinib Resistant : C4
EGFR-SEPTIN14 fusion + EGFR amplification	Colorectal Cancer	EGFR-SEPTIN14 fusion + EGFR amplification	Colorectal Cancer	erlotinib Sensitive: C4 – Case Studies erlotinib Sensitive : C4	erlotinib Sensitive: C4 – Case Studies erlotinib Sensitive : C4
EGFR-SEPTIN14 fusion + EGFR amplification	Colorectal Cancer	EGFR-SEPTIN14 fusion + EGFR amplification	Colorectal Cancer	bevacizumab Resistant: C4 – Case Studies bevacizumab Resistant : C4	bevacizumab Resistant: C4 – Case Studies bevacizumab Resistant : C4
EGFR-SEPTIN14 fusion	Non Small Cell Lung Cancer	EGFR-SEPTIN14 fusion	Non Small Cell Lung Cancer	osimertinib Sensitive: C4 – Case Studies osimertinib Sensitive : C4	osimertinib Sensitive: C4 – Case Studies osimertinib Sensitive : C4